Share:
Basel, June 28, 2021 Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective September 1, 2021.
Steven Baert, currently Chief People & Organization Officer, will step down from the Executive Committee of Novartis, effective June 30, 2021 after 15 years with the company and almost 8 years in position. Vicki Rawlinson, US Head People & Organization will lead the function ad-interim until Dr. Kowalski takes over.
Dr. Kowalski is a senior drug development and regulatory executive with over 25 years of industry experience. He has successfully built and led Global Regulatory Affairs, a large organization within the Novartis Drug Development with many interfaces into our commercial and R&D organizations on global and local levels. Prior
Novartis Pharma AG: Novartis appoints Rob Kowalski as Chief People & Organization Officer
Basel, June 28, 2021 - Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective September 1, 2021.
Steven Baert, currently Chief People & Organization Officer, will step down from the Executive Committee of Novartis, effective June 30, 2021 after 15 years with the company and almost 8 years in position. Vicki Rawlinson, US Head People & Organization will lead the function ad-interim until Dr. Kowalski takes over.
Novartis AG (via Public) / Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland (Form 6-K) publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.
Unbossing Leaders at Novartis AG
A Conversation With Steven Baert
Steven Baert
CliftonStrengths Top 5: Relator | Achiever | Responsibility | Self-Assurance | Arranger
While some leaders are concerned about remote employees productivity in a boss-less workspace,
The concept is part of a development initiative, the Unbossed Leadership Experience, that the $48 billion The real value of human capital is the ability to innovate in extremely complex situations, Novartis CHRO
That kind of leadership, as Baert tells
Gallup Managing Director Larry Emond in this CHRO Conversation, generates better solutions to tougher problems. And Baert says that the teams of Unbossed leaders aren t less productive indeed, they re more engaged and motivated because they have greater purpose and impact.
Pharming Reports on Annual General Meeting of Shareholders
LEIDEN, The Netherlands, May 19, 2021 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.
As a result, Sijmen de Vries was reappointed for four years as Chief Executive Officer and an Executive Director of the Board of Directors. In addition, further to the announcement on 23 March 2021, Jabine van der Meijs, Steven Baert and Leonard Kruimer have been appointed as Non-Executive Directors to the Board of Directors and Aad de Winter and Barrie Ward have retired from the Board of Directors, effective immediately.